Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (PsAer-IgY)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Mukoviszidose Institut gGmbH
Information provided by (Responsible Party):
Mukoviszidose Institut gGmbH Identifier:
First received: October 18, 2011
Last updated: February 20, 2014
Last verified: January 2014

The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.

Condition Intervention Phase
Cystic Fibrosis
Drug: IgY
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients

Resource links provided by NLM:

Further study details as provided by Mukoviszidose Institut gGmbH:

Primary Outcome Measures:
  • Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • • Change in FEV 1.0 from day 0 to each visit [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Change in BMI from day 0 to each visit [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Number of exacerbations [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Number of days of illness in hospital and at home, i.e. out of school or work [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Control of use of antibiotics, especially anti-pseudomonas antibiotics -measured as days with antibiotic treatment [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Change in values of serologic tests for PA precipitins from day 0 to each visit (if applicable) [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Good tolerability and comparable number and quality of adverse events like placebo group [ Time Frame: max. 24 months ] [ Designated as safety issue: Yes ]
  • • Sputum or throat cough swab or endolaryngeal suction cultures for bacteria and fungi [ Time Frame: max. 24 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 180
Study Start Date: October 2011
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IgY, gargling solution
Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
Drug: IgY
Avian polyclonal anti-pseudomonas antibodies (IgY)
Placebo Comparator: Placebo, gargling solution
70 ml gargling solution without antibodies, once daily
Drug: Placebo
Placebo, 70 ml gargling solution, once daily

Detailed Description:

This is a double -blind, placebo controlled study in which the investigational drug and the reference placebo group are gargled and swallowed. 70 ml IgY/ placebo solution is gargled every night for two minutes (for maximal 24 months) The design will include the recruitment of 144 patients randomized in two groups (72 per treatment group) In order to compensate for dropouts (i.e. patients dropping out prior to 24 months without having an event) the total sample size is planned to be approximately 180 (i.e. ~20 % dropout rate).

During the two years of treatment, subjects will be examined at the clinic every 3 months regarding safety and efficacy of the medication.

For more information please see The IMPACTT Project is funded by EU within the Framework 7 Program. PsAer-IgY Studie is part of IMPACTT Project (Workpackage 2).


Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CF patients diagnosed according to specific clinical features and either a positive sweat chloride in double proofs or presence of disease-associated CFTR mutations in both alleles
  • Males and females 5 years of age and above (being able to gargle)
  • CF patients having a FEV1 value between 50% and 130% of predicted value (according to Knudson formula)
  • CF patients who have had one to several sputum or throat cough swabs or endolaryngeal suction cultures positive for PA within the last three years and for whom PA has been successfully eradicated.
  • Sputum / throat cough swab/ endolaryngeal suction culture negative for PA and other gram-negative bacteria on study entry.
  • Patients and/ or their legal representative who are willing and able to give informed consent/ assent to participate in the study after thorough information
  • Subjects of child bearing potential and who are sexually active must meet the contraception requirements (i.e. oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms).

Exclusion Criteria:

  • Microbiologic or serologic evidence of chronic infection with PA. Definition of chronic PA infection: Three cultures (sputum or throat cough swabs or endolaryngeal suction) have been positive for PA for 6 consecutive months (at least 3 cultures have to be taken) or more, .
  • Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for gram-negative bacteria, such as PA, S. maltophilia, B. cepacia, A. xylosoxidans (eradication before entry in study is possible), Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for atypical Mycobacteria and / or Aspergillus fumigates, associated with clinical symptoms that may necessitate specific treatment.
  • History of allergy/hypersensitivity to hens' egg proteins (including medication allergy) that is deemed relevant to the trial by the investigator. "Relevance" in this context refers to any increased risk of hypersensitivity reaction to trial medication.
  • Patient with a known relevant substance abuse, including alcohol or drug abuse.
  • Start of a new concomitant or chronic medication for CF within 4 weeks before inclusion.
  • Clinically relevant diseases or medical conditions other than CF or CF-related conditions that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This includes, but is not limited to, significant hematological, hepatic, renal, cardiovascular, and neurological diseases (diabetic patients may participate if their disease is under good control prior to inclusion).
  • Participation in another study with an investigational drug within one month or 6 half-lives (whichever is greater) preceding the inclusion.
  • The patient is an employee of the investigator or the institution with direct involvement in the trial or other trials under the direction of the investigator or their members.
  • Patients who are pregnant cannot be included into the study. This will be tested at inclusion visit with a urine pregnancy test (in female patients older than 10 years with secondary sexual characteristics)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01455675

Contact: Jutta Bend, Dr. +49 (0)228 ext 9878047

Clinic of Pediatric Respiratory Diseases, Infectious Diseases and Travel Clinic Recruiting
Brussels, Belgium, 1090
Contact: Anne Malfroot, Prof. Dr.         
Principal Investigator: Anne Malfroot, Prof. Dr.         
Hôpital Universitaire Erasme, Service de Pneumologie Recruiting
Brussels, Belgium
Contact: Christiane Knoop, Prof. Dr.         
Principal Investigator: Christiane Knoop, Prof. Dr.         
University Hospital Leuven, Kindergeneeskunde Recruiting
Leuven, Belgium, 3000
Contact: Christiane De Boeck, Prof.         
Principal Investigator: Christiane De Boeck, Prof.         
Luisenhospital Aachen Recruiting
Aachen, Germany, 52064
Contact: Dirk Steffen         
Principal Investigator: Dirk Steffen, Dr.         
Charité, Christiane Herzog Zentrum Recruiting
Berlin, Germany, 13353
Contact: Doris Staab, Dr.         
Principal Investigator: Doris Staab, Dr.         
Klinikum der Ruhr Universität Bochum Recruiting
Bochum, Germany, 44791
Contact: Manfred Ballmann, Prof. Dr.         
Principal Investigator: Manfred Ballmann, Prof. Dr.         
University Dresden Recruiting
Dresden, Germany, 01307
Contact: Jutta Hammermann, Dr.         
Principal Investigator: Jutta Hammermann, Dr.         
Universitätsklinikum Düsseldorf Recruiting
Düsseldorf, Germany, 40225
Contact: Antje Schuster, Prof. Dr.         
Principal Investigator: Antje Schuster, Prof. Dr.         
Universitätsklinikum Essen Recruiting
Essen, Germany, 45122
Contact: Uwe Mellies, Dr.         
Principal Investigator: Uwe Mellies, Dr.         
Klinikum der Johann-Wolfgang- Goethe Universität Frankfurt Recruiting
Frankfurt, Germany
Contact: Wolfgang Gleiber, Dr.         
Principal Investigator: Wolfgang Gleiber, Dr.         
Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin Recruiting
Freiburg, Germany, 79106
Contact: Andrea Heinzmann, Prof. Dr.         
Principal Investigator: Andrea Heinzmann, Prof. Dr.         
Universitätsklinikum Gießen und Marburg GmbH Recruiting
Gießen, Germany, 35392
Contact: Lutz Nährlich, Dr.         
Principal Investigator: Lutz Nährlich, Dr.         
MH Hannover (adults) Recruiting
Hannover, Germany, 30625
Contact: Tobias Welte, Prof. Dr.         
Principal Investigator: Tobias Welte, Prof. Dr.         
MH Hannover (children) Recruiting
Hannover, Germany, 30625
Contact: Sibylle Junge, Dr.         
Principal Investigator: Sibylle Junge, Dr.         
Universitätsklinik Jena, Mukoviszidosezentrum Recruiting
Jena, Germany, 07740
Contact: Jochen Mainz, Dr.         
Principal Investigator: Jochen Mainz, Dr.         
Städtisches Krankenhaus Kiel GmbH Recruiting
Kiel, Germany, 24116
Contact: Andreas Claaß         
Principal Investigator: Andreas Claaß, PD Dr.         
Universitätsklinik Köln Recruiting
Köln, Germany, 50924
Contact: Silke van Koningsbruggen-Rietschel, Dr.         
Principal Investigator: Silke van Koningsbruggen-Rietschel, Dr.         
Universitätsklinikum Mainz Recruiting
Mainz, Germany, 55131
Contact: Krystyna Poplawska, Dr.         
Principal Investigator: Krystyna Poplawska, Dr.         
Universitätsklinik Tübingen Recruiting
Tübingen, Germany, 72076
Contact: Joachim Riethmüller, Dr.         
Principal Investigator: Joachim Riethmüller, Dr.         
Cork University Hospital Recruiting
Cork, Ireland
Contact: Muireann Ni Chroinin, Dr.         
Principal Investigator: Muireann Ni Chroinin, Dr.         
Our Lady´s Children´s Hospital Recruiting
Dublin, Ireland, 12
Contact: Desmond Cox, Dr.         
Principal Investigator: Desmond Cox, Dr.         
Tallagh Hospital Recruiting
Dublin, Ireland, 24
Contact: Basil Elnazir, Dr.         
Principal Investigator: Basil Elnazir, Dr.         
Mid-Western Regional Hospital Recruiting
Limerick, Ireland
Contact: Barry Linnane, Dr.         
Principal Investigator: Barry Linnane, Dr.         
Centro Regionale Toscano di Riferimento per la Fibrosi Cistica Recruiting
Firenze, Italy, 50139
Contact: Cesare Braggion, Dr.         
Principal Investigator: Cesare Braggion, Dr.         
Istituto Ospedale Giannina Gaslini Recruiting
Genova, Italy, 16100
Contact: Laura Minicucci, Dr.         
Principal Investigator: Laura Minicucci, Dr.         
Centro Regionale Fibrosi Cisica Lazio Recruiting
Roma, Italy, 00161
Contact: Serena Quattrucci, Dr.         
Principal Investigator: Serena Quattrucci, Dr.         
Azienda Ospedaliera Universitaria Integrata di Verona Recruiting
Verona, Italy, 37126
Contact: Barouk Assael, Prof. Dr..         
Principal Investigator: Barouk Assael, Prof. Dr.         
Karolinska University Hospital, Huddinge - CF-Centre Recruiting
Stockholm, Sweden, 141 86
Contact: Ferenc Karpati         
Principal Investigator: Ferenc Karpati, MD         
Uppsala University Childrens Hospital, Akademiska sjukhuset, CF center Recruiting
Uppsala, Sweden, 75185
Contact: Annika Ericsson Hollsing, Dr. Dr.         
Principal Investigator: Annika Ericsson Hollsing, Dr. Dr.         
Sponsors and Collaborators
Mukoviszidose Institut gGmbH
Principal Investigator: Antje Schuster, Prof. Dr. Universitätsklinikum Düsseldorf
  More Information

Additional Information:
No publications provided

Responsible Party: Mukoviszidose Institut gGmbH Identifier: NCT01455675     History of Changes
Other Study ID Numbers: PsAer-IgY
Study First Received: October 18, 2011
Last Updated: February 20, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Mukoviszidose Institut gGmbH:
cystic fibrosis

Additional relevant MeSH terms:
Cystic Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Pharmaceutical Solutions
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 27, 2015